ANDA 84804, held by Purepac Pharm. Meprobamate.
As of Nov 14, 2026, ANDA 84804 (Meprobamate), held by Purepac Pharm, was not approved, with 0 approved supplements and 0 published complete response letters.
| Meprobamate200MG · tablet;oral | Meprobamate | Discontinued |
| Meprobamate400MG · tablet;oral | Meprobamate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters